Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.

Scientific reports - 22 Mar 2024

De Marchi Tommaso, Lai Chun-Fui, Simmons Georgia M, Goldsbrough Isabella, Harrod Alison, Lam Thai, Buluwela Lakjaya, Kjellström Sven, Brueffer Christian, Saal Lao H, Malmström Johan, Ali Simak, Niméus Emma

Abstract excerpt

Three quarters of all breast cancers express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastatic breast cancer, in particular to aromatase inhibitors. ESR1 mutations promote constitutive ER activity and affect other signaling pathways, allowing cancer cells to proliferate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cyclin-Dependent Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Estrogens

Share to Phosphoproteins

Share to Proteome

Share to Proteomics

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 38519482
DOI: 10.1038/s41598-024-56412-8
PMCID: PMC10959978

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling.PMID 38519482Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer.Semantic proximity Read ↗

<i>ESR1</i> mutant breast cancers show elevated basal cytokeratins and immune activationSemantic proximity Read ↗

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferationSemantic proximity Read ↗

ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.Semantic proximity Read ↗

Characterization of ESR1 alterations in patients with breast and gynecologic cancers.Semantic proximity Read ↗

RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.Semantic proximity Read ↗

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Semantic proximity Read ↗

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor-and stem-like cell expansion in the context of <i>ESR1</i> mutationSemantic proximity Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.